PEDIATRICS Vol. 80 No. 4 October 1987, pp. 473-480
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, P. F.
Right arrow Articles by Karzon, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, P. F.
Right arrow Articles by Karzon, D. T.

Candidate Rotavirus Vaccine (Rhesus Rotavirus Strain) in Children: An Evaluation

Peter F. Wright MD1, Takeshi Tajima MD1, Juliette Thompson MSN1, Knstina Kokubun BA1, Albert Kapikian MD1, and David T. Karzon MD1

1 From the Department of Pediatrics, Vanderbilt University, Nashville, Tennessee, and Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Fifty children, 3 months to 12 years of age, were given an experimental, orally administered, live attenuated rotavirus vaccine. Overall evidence of vaccine effectiveness as judged by vaccine virus shedding or a serologic response was seen in 82% of vaccinees. No clinical illness was seen in the rotavirus vaccinees when compared with 40 concurrently studied control children. No transmission to control children was observed even with close daily contact in a day-care setting. Young infants, generally less than 1 year of age, who had not previously experienced wild-type rotavirus infection shed significantly more vaccine virus. Limitation of virus shedding in those already exposed may be related to a prompt copro-IgA response which was significantly elevated by three days after vaccination. In summary, the development of this rotavirus vaccine, rhesus rotavirus-MMU-18006, is a promising step in the development of immunoprophylaxis against this major enteric pathogen.

Key Words: rotavirus vaccine • rhesus rotavirus strain

Submitted on August 1, 1986
Accepted on December 17, 1986